Salix Pharmaceuticals, Ltd. Expands XIFAXAN(R) Intellectual Property

RALEIGH, N.C.--(BUSINESS WIRE)--July 5, 2006--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP - News) today announced that the Company has entered into an agreement with Cedars-Sinai Medical Center, or CSMC, for the right to use U.S. Patent No. 6,861,053 and U.S. Patent Application No. 11/234,516 relating to methods of diagnosis and treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth. Under the agreement, CSMC grants Salix an exclusive worldwide license to make, have made, use, sell and have sold and import licensed products related to the use of rifaximin, which we market in the United States under the trade name XIFAXAN®, with a right to sublicense. CSMC also grants Salix a nonexclusive license to use any unpublished research and development information, know-how and technical data of CSMC as necessary to exploit all rights granted to Salix with respect to rifaximin, with a right to sublicense.

Back to news